E3 ligase UHRF2 hijacks nuclear TBK1 to epigenetically repress type I interferons expression

  • Int J Biol Sci. 2026 May 18;22(10):5385-5398. doi: 10.7150/ijbs.135125.
Wenwen Huang  1  2 Renjie Song  3 Qicong Shen  2 Yang Shi  3 Xi Wang  1 Nan Li  2 Qian Zhang  2 Xuetao Cao  1  3
Affiliations
  • 1. Institute of Immunology, Zhejiang University School of Medicine, Hangzhou 310058, China.
  • 2. National Key Laboratory of Immunity and Inflammation, Institute of Immunology, Naval Medical University, Shanghai 200433, China.
  • 3. Department of Immunology, Institute of Basic Medical Sciences & School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China.
Abstract

The rapid induction of type I interferons (IFN-I) by innate signaling is indispensable for host defense; however, its uncontrolled expression invariably leads to autoimmune diseases. Here, we reveal that the E3 ubiquitin Ligase UHRF2 functions as a highly specific epigenetic repressor of IFN-I gene transcription. During viral Infection, activated TBK1 undergoes nuclear translocation, where it is hijacked by UHRF2 to achieve gene-specific targeting at IFN-I loci. Upon recruitment to IFN-I loci, UHRF2 physically interacts with histone deacetylase 1 (HDAC1), catalyzes atypical K29-linked polyubiquitination and prevents HDAC1 from degradation. This stabilized UHRF2-HDAC1 complex actively erases the lactylation of histone H4 at lysine 12 (H4K12la), thereby silencing IFN-I transcription. To mount an effective initial Antiviral response, IFN-I signaling feedback transiently downregulates UHRF2 expression. Consequently, UHRF2-deficient mice exhibit profound resistance to lethal virus Infection in vivo due to IFN-I overproduction. These findings uncover a highly coordinated mechanism wherein nuclear TBK1, UHRF2, and HDAC1 converge to epigenetically regulate immune homeostasis through histone delactylation, identifying UHRF2 as a potential therapeutic target for virus Infection or autoimmune diseases.

Keywords
UHRF2; antiviral immunity; epigenetic regulation; histone lactylation; type I interferons.
Products